Kt Corporation ADR Stock
Your prediction
Kt Corporation ADR Stock
We can see a decrease in the price for Kt Corporation ADR. Compared to yesterday it has lost -€0.300 (-1.860%).
Pros and Cons of Kt Corporation ADR in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Kt Corporation ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Kt Corporation ADR | -1.860% | -2.500% | -0.637% | -9.302% | -1.266% | 39.286% | 26.829% |
| Freenet AG | -0.250% | -2.547% | -0.336% | -16.124% | -19.593% | 8.708% | 14.038% |
| Philippine Long Distance Telephone Company ADR | -0.600% | -1.754% | 4.348% | -14.721% | -6.667% | -19.231% | -16.000% |
| Telekom Austria AG | 0.390% | 0.990% | 1.796% | 9.442% | 13.586% | 52.012% | 35.819% |
News
Kymera Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch